Search Results - "Gandhi, Leena"

Alectinib in ALK -positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial by Shaw, Alice T, Dr, Gandhi, Leena, MD, Gadgeel, Shirish, Prof, Riely, Gregory J, MD, Cetnar, Jeremy, MD, West, Howard, MD, Camidge, D Ross, MD, Socinski, Mark A, Prof, Chiappori, Alberto, MD, Mekhail, Tarek, MD, Chao, Bo H, MD, Borghaei, Hossein, DO, Gold, Kathryn A, MD, Zeaiter, Ali, MD, Bordogna, Walter, PhD, Balas, Bogdana, MD, Puig, Oscar, PhD, Henschel, Volkmar, PhD, Ou, Sai-Hong Ignatius, Prof

“…Summary Background Alectinib—a highly selective, CNS-active, ALK inhibitor—showed promising clinical activity in crizotinib-naive and crizotinib-resistant…”
Get full text

Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid by Sowerby, Laura, Dewan, Anna K, Granter, Scott, Gandhi, Leena, LeBoeuf, Nicole R

Get more information

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer by Garon, Edward B, Rizvi, Naiyer A, Hui, Rina, Leighl, Natasha, Balmanoukian, Ani S, Eder, Joseph Paul, Patnaik, Amita, Aggarwal, Charu, Gubens, Matthew, Horn, Leora, Carcereny, Enric, Ahn, Myung-Ju, Felip, Enriqueta, Lee, Jong-Seok, Hellmann, Matthew D, Hamid, Omid, Goldman, Jonathan W, Soria, Jean-Charles, Dolled-Filhart, Marisa, Rutledge, Ruth Z, Zhang, Jin, Lunceford, Jared K, Rangwala, Reshma, Lubiniecki, Gregory M, Roach, Charlotte, Emancipator, Kenneth, Gandhi, Leena

“…Pembrolizumab, an inhibitor of programmed cell death 1 (PD-1), produced responses in 24% of patients with non–small-cell lung cancer, with a median overall…”
Get full text

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study by Langer, Corey J, Dr Prof, Gadgeel, Shirish M, Prof, Borghaei, Hossein, DO, Papadimitrakopoulou, Vassiliki A, Prof, Patnaik, Amita, MD, Powell, Steven F, MD, Gentzler, Ryan D, MD, Martins, Renato G, Prof, Stevenson, James P, MD, Jalal, Shadia I, MBBS, Panwalkar, Amit, MD, Yang, James Chih-Hsin, Prof, Gubens, Matthew, MD, Sequist, Lecia V, MD, Awad, Mark M, MD, Fiore, Joseph, PharmD, Ge, Yang, PhD, Raftopoulos, Harry, MD, Gandhi, Leena, Prof

“…Summary Background Limited evidence exists to show that adding a third agent to platinum-doublet chemotherapy improves efficacy in the first-line advanced…”
Get full text

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK -rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study by Gadgeel, Shirish M, MD, Gandhi, Leena, MD, Riely, Gregory J, MD, Chiappori, Alberto A, MD, West, Howard L, MD, Azada, Michele C, MPH, Morcos, Peter N, PharmD, Lee, Ruey-Min, MD, Garcia, Linta, PharmD, Yu, Li, PhD, Boisserie, Frederic, MSc, Di Laurenzio, Laura, PhD, Golding, Sophie, MSc, Sato, Jotaro, MS, Yokoyama, Shumpei, MS, Tanaka, Tomohiro, MS, Ou, Sai-Hong Ignatius, Dr

“…Summary Background Patients with non-small-cell lung cancer (NSCLC) and ALK rearrangements generally have a progression-free survival of 8–11 months while on…”
Get full text

Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients by Paweletz, Cloud P, Sacher, Adrian G, Raymond, Chris K, Alden, Ryan S, O'Connell, Allison, Mach, Stacy L, Kuang, Yanan, Gandhi, Leena, Kirschmeier, Paul, English, Jessie M, Lim, Lee P, Jänne, Pasi A, Oxnard, Geoffrey R

“…Tumor genotyping is a powerful tool for guiding non-small cell lung cancer (NSCLC) care; however, comprehensive tumor genotyping can be logistically…”
Get full text

Activity and safety of crizotinib in patients with ALK -positive non-small-cell lung cancer: updated results from a phase 1 study by Camidge, D Ross, Dr, Bang, Yung-Jue, Prof, Kwak, Eunice L, MD, Iafrate, A John, MD, Varella-Garcia, Marileila, Prof, Fox, Stephen B, Prof, Riely, Gregory J, MD, Solomon, Benjamin, MBBS, Ou, Sai-Hong I, MD, Kim, Dong-Wan, Prof, Salgia, Ravi, Prof, Fidias, Panagiotis, MD, Engelman, Jeffrey A, MD, Gandhi, Leena, MD, Jänne, Pasi A, MD, Costa, Daniel B, MD, Shapiro, Geoffrey I, MD, LoRusso, Patricia, DO, Ruffner, Katherine, MD, Stephenson, Patricia, ScD, Tang, Yiyun, PhD, Wilner, Keith, PhD, Clark, Jeffrey W, MD, Shaw, Alice T, MD

“…Summary Background ALK fusion genes occur in a subset of non-small-cell lung cancers (NSCLCs). We assessed the tolerability and activity of crizotinib in…”
Get full text

Crizotinib for ALK-Rearranged Non―Small Cell Lung Cancer: A New Targeted Therapy for a New Target by GANDHI, Leena, JÄNNE, Pasi A

“…Crizotinib (PF02341066, Xalkori; Pfizer) was recently approved by the U.S. Food and Drug Administration for treatment of ALK-positive non-small cell lung…”
Get full text

Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan by Gray, Jhanelle E, Heist, Rebecca S, Starodub, Alexander N, Camidge, D Ross, Kio, Ebenezer A, Masters, Gregory A, Purcell, W Thomas, Guarino, Michael J, Misleh, Jamal, Schneider, Charles J, Schneider, Bryan J, Ocean, Allyson, Johnson, Tirrell, Gandhi, Leena, Kalinsky, Kevin, Scheff, Ronald, Messersmith, Wells A, Govindan, Serengulam V, Maliakal, Pius P, Mudenda, Boyd, Wegener, William A, Sharkey, Robert M, Goldenberg, David M

“…We evaluated a Trop-2-targeting antibody conjugated with SN-38 in metastatic small cell lung cancer (mSCLC) patients. Sacituzumab govitecan was studied in…”
Get full text

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors by GANDHI, Leena, CAMIDGE, D. Ross, DIVE, Caroline, ENSCHEDE, Sari H, NOLAN, Cathy, CHIU, Yi-Lin, BUSMAN, Todd, HAO XIONG, KRIVOSHIK, Andrew P, HUMERICKHOUSE, Rod, SHAPIRO, Geoffrey I, RUDIN, Charles M, DE OLIVEIRA, Moacyr Ribeiro, BONOMI, Philip, GANDARA, David, KHAIRA, Divis, HANN, Christine L, MCKEEGAN, Evelyn M, LITVINOVICH, Elizabeth, HEMKEN, Philip M

“…Resistance to chemotherapy-induced apoptosis represents a major obstacle to cancer control. Overexpression of Bcl-2 is seen in multiple tumor types and…”
Get full text

Phase I Study of Neratinib in Combination With Temsirolimus in Patients With Human Epidermal Growth Factor Receptor 2–Dependent and Other Solid Tumors by GANDHI, Leena, BAHLEDA, Rastislav, KRYGOWSKI, Mizue, YALI LIANG, TURNBULL, Kathleen W, SHAPIRO, Geoffrey I, SORIA, Jean-Charles, TOLANEY, Sara M, KWAK, Eunice L, CLEARY, James M, PANDYA, Shuchi S, HOLLEBECQUE, Antoine, ABBAS, Richat, ANANTHAKRISHNAN, Revathi, BERKENBLIT, Anna

“…Human epidermal growth factor (HER) -mediated signaling is critical in many cancers, including subsets of breast and lung cancer. HER family members signal via…”
Get full text

Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study by Gadgeel, Shirish M., Stevenson, James P., Langer, Corey J., Gandhi, Leena, Borghaei, Hossein, Patnaik, Amita, Villaruz, Liza C., Gubens, Matthew, Hauke, Ralph, Yang, James Chih-Hsin, Sequist, Lecia V., Bachman, Robert, Saraf, Sanatan, Raftopoulos, Harry, Papadimitrakopoulou, Vassiliki

“…•KEYNOTE-021 A-C evaluated pembrolizumab + platinum chemotherapy in advanced NSCLC.•No dose-limiting toxicity occurred in any cohort at pembrolizumab 2 or 10…”
Get full text

Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer by Heist, Rebecca S., Duda, Dan G., Sahani, Dushyant V., Ancukiewicz, Marek, Fidias, Panos, Sequist, Lecia V., Temel, Jennifer S., Shaw, Alice T., Pennell, Nathan A., Neal, Joel W., Gandhi, Leena, Lynch, Thomas J., Engelman, Jeffrey A., Jain, Rakesh K.

“…Significance A better mechanistic understanding of the survival benefits and identification of biomarkers of response would greatly enhance the optimal…”
Get full text

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC) by Brahmer, Julie R, Govindan, Ramaswamy, Anders, Robert A, Antonia, Scott J, Sagorsky, Sarah, Davies, Marianne J, Dubinett, Steven M, Ferris, Andrea, Gandhi, Leena, Garon, Edward B, Hellmann, Matthew D, Hirsch, Fred R, Malik, Shakuntala, Neal, Joel W, Papadimitrakopoulou, Vassiliki A, Rimm, David L, Schwartz, Lawrence H, Sepesi, Boris, Yeap, Beow Yong, Rizvi, Naiyer A, Herbst, Roy S

“…Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for over 85% of all cases. Until…”
Get full text

A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer by Nadal, Ernest, Saleh, Mansoor, Aix, Santiago Ponce, Ochoa-de-Olza, Maria, Patel, Sandip Pravin, Antonia, Scott, Zhao, Yumin, Gueorguieva, Ivelina, Man, Michael, Estrem, Shawn T, Liu, Jiangang, Avsar, Emin, Lin, Wen Hong, Benhadji, Karim A, Gandhi, Leena, Guba, Susan C, Diaz, Inmaculada Ales

“…In this phase Ib/II open-label study, tumor immune suppression was targeted in patients with advanced refractory solid tumors and patients with…”
Get full text

Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study by Horn, Leora, Gettinger, Scott N., Gordon, Michael S., Herbst, Roy S., Gandhi, Leena, Felip, Enriqueta, Sequist, Lecia V., Spigel, David R., Antonia, Scott J., Balmanoukian, Ani, Cassier, Philippe A., Liu, Bo, Kowanetz, Marcin, O'Hear, Carol, Fassò, Marcella, Grossman, William, Sandler, Alan, Soria, Jean-Charles

“…Atezolizumab, an anti-programmed death-ligand 1 (PD-L1) antibody, inhibits PD-L1:PD-1 and PD-L1:B7.1 interactions, restoring anticancer immunity. Here, we…”
Get full text

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer by Yang, James Chih-Hsin, Ou, Sai-Hong Ignatius, De Petris, Luigi, Gadgeel, Shirish, Gandhi, Leena, Kim, Dong-Wan, Barlesi, Fabrice, Govindan, Ramaswamy, Dingemans, Anne-Marie C, Crino, Lucio, Lena, Herve, Popat, Sanjay, Ahn, Jin Seok, Dansin, Eric, Golding, Sophie, Bordogna, Walter, Balas, Bogdana, Morcos, Peter N, Zeaiter, Ali, Shaw, Alice T

“…Alectinib demonstrated clinical efficacy and an acceptable safety profile in two phase II studies (NP28761 and NP28673). Here we report the pooled efficacy and…”
Get more information

Phase I Study of Pazopanib in Patients with Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study by SHIBATA, Stephen I, CHUNG, Vincent, O'NEIL, Bert H, SARANTOPOULOS, John, LORUSSO, Patricia, RUDEK, Michelle A, DOWLATI, Afshin, MULKERIN, Daniel L, BELANI, Chandra P, GANDHI, Leena, LAU, S. Cecilia, IVY, S. Percy, SYNOLD, Timothy W, NEWMAN, Edward M, LONGMATE, Jeffrey A, BENJAMIN SUTTLE, A, OTTESEN, Lone H, LENZ, Heinz-Josef, KUMMAR, Shivaani, HARVEY, R. Donald, HAMILTON, Anne L

“…Pazopanib is a potent, multitargeted receptor tyrosine kinase inhibitor; however, there is limited information regarding the effects of liver function on…”
Get full text

633 A Phase 1a/1b, dose-escalation/dose-expansion study of NPX267 in subjects with solid tumors known to express HHLA2 by Naing, Aung, Rivera, Ismael Rodriguez, Johnson, Melissa, Gainor, Justin, Ji, Yuan, Forde, Patrick, Cheng, Haiying, Gandhi, Leena, McDermott, David F

“…BackgroundHHLA2 (B7H7) is a B7 family member which suppresses T and NK cell activation through an inhibitory receptor, KIR3DL3,1 2 and stimulates activation…”
Get full text

Abstract CT075: KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC by Gandhi, Leena, Rodgríguez-Abreu, Delvys, Gadgeel, Shirish, Esteban, Emilio, Felip, Enriqueta, Angelis, Flávia De, Domine, Manuel, Clingan, Philip, Hochmair, Maximilian J, Powell, Steven, Cheng, Susanna Yee-Shan, Bischoff, Helge G, Peled, Nir, Grossi, Francesco, Jennens, Ross R, Reck, Martin, Hui, Rina, Garon, Edward B, Boyer, Michael, Rubio-Viqueira, Belén, Novello, Silvia, Kurata, Takayasu, Gray, Jhanelle E, Vida, John J, Wei, Ziwen, Yang, Jing, Raftopoulos, Harry, Pietanza, M. Catherine, Garassino, Marina C

“…Abstract Background: The premise that chemotherapy and immunotherapy may provide greater benefit than pembro or chemotherapy alone was supported by KEYNOTE-021…”
Get full text